Scopic Research has added a performance / opinion piece to its multi asset DNA reports to help advisers and paraplanners when monitoring multi-asset funds.
The following fund suites have been covered so far:
BNY Mellon Multi Asset Funds
Cornelian Risk Managed Funds
Downing Fox Funds
Hawksmoor
HSBC Global Strategy Portfolios
Legal & General Multi Index
Legal & General Multi Index Income
Rathbone Multi Asset Portfolios
Rathbone Greenbanj Multi Asset Portfolios
Scopic says all funds within the Scopic Multi Asset DNA Reports service will eventually have the Opinion section included.
This will happen as their respective annual review meetings have been completed.
Paul Ilott, managing director of Scopic, said: “Together with the existing investment journey section in our Multi Asset DNA Reports the new Opinion / performance review section will help to deepen advisers’ and paraplanners’ understanding of how an individual multi-asset fund is expected to perform, and whether these expectations have broadly been met.“
“Additionally, it will help advisers to understand, explain and tolerate, tepid periods of performance when our research indicates that this was probably what we should have been expected given the portfolio team’s approach. Equally, it will help advisers to be more critical when it’s warranted.”
“Advisers/paraplanners now have this additional analysis at their disposal to use in conversations with their own clients if they so wish. This is especially important given the requirement placed upon advisers to ensure that their clients know what they have invested in and how it’s likely to behave – think Consumer Duty.”
